New York State Common Retirement Fund lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 180,924 shares of the biopharmaceutical company’s stock after selling 3,196 shares during the period. New York State Common Retirement Fund owned about 0.15% of Alnylam Pharmaceuticals worth $34,160,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ALNY. Koshinski Asset Management Inc. bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $44,000. Capital Analysts LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $68,000. Berman Capital Advisors LLC boosted its position in Alnylam Pharmaceuticals by 179.7% during the second quarter. Berman Capital Advisors LLC now owns 414 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 266 shares during the period. Itau Unibanco Holding S.A. bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $101,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Alnylam Pharmaceuticals by 62.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 601 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 231 shares during the period. Institutional investors and hedge funds own 93.45% of the company’s stock.
In other Alnylam Pharmaceuticals news, insider Akshay Vaishnaw sold 2,879 shares of the business’s stock in a transaction on Thursday, December 23rd. The shares were sold at an average price of $190.93, for a total transaction of $549,687.47. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 33,978 shares of the business’s stock in a transaction on Friday, November 12th. The shares were sold at an average price of $171.52, for a total transaction of $5,827,906.56. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by insiders.
A number of brokerages have weighed in on ALNY. UBS Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $141.00 to $215.00 in a research report on Monday, October 4th. Morgan Stanley cut their price objective on shares of Alnylam Pharmaceuticals from $242.00 to $226.00 and set an “overweight” rating for the company in a research report on Friday, October 29th. Needham & Company LLC raised their price objective on shares of Alnylam Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, November 22nd. BMO Capital Markets restated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, October 31st. Finally, SVB Leerink restated a “hold” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, December 1st. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $198.13.
Shares of NASDAQ ALNY opened at $194.35 on Monday. The company has a quick ratio of 4.22, a current ratio of 4.38 and a debt-to-equity ratio of 0.57. Alnylam Pharmaceuticals, Inc. has a 52 week low of $124.00 and a 52 week high of $212.00. The firm’s fifty day moving average is $184.28 and its 200 day moving average is $185.63. The company has a market cap of $23.24 billion, a price-to-earnings ratio of -27.26 and a beta of 0.91.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, October 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.51) by ($0.21). Alnylam Pharmaceuticals had a negative return on equity of 94.37% and a negative net margin of 111.82%. The firm had revenue of $187.63 million during the quarter, compared to analysts’ expectations of $218.69 million. During the same period in the previous year, the firm earned ($2.18) earnings per share. The firm’s quarterly revenue was up 49.1% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.54 earnings per share for the current year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
Featured Article: Return on Investment (ROI) Defined, Explained
Want More Great Investing Ideas?